Personal Information
Date of Birth: April 1976
Nationality: China
Affiliation: Yichun University
Professional Title: Professor
Degree: PhD
Email: cui_jj@hotmail.com
Research Interests
Focusing on the molecular mechanisms of tumor metabolic reprogramming, drug resistance, and epigenetic regulation in breast cancer, especially triple-negative breast cancer (TNBC). Main research directions include tumor suppressor gene function, glycolysis modification, ferroptosis regulation, and targeted reversal of chemotherapy resistance.
Education Background
2003.09-2006.12 PhD, Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, China
1999.09-2002.06 Master of Science, Shandong Agricultural University, China
1995.09-1999.07 Bachelor of Science, Shanghai Normal University, China
Research & Professional Experience
2015.12-Present Professor, School of Medicine, Yichun University, China
2014.08-2015.12 Postdoctoral Fellow, School of Medicine, University of Kentucky, USA
2011.08-2014.08 Postdoctoral Fellow, School of Medicine, University of Cincinnati, USA
2009.09-2011.09 Project Manager,Beijing Biotech Pharmaceuticals, China
Funded projects (Principal Investigator)
1. National Natural Science Foundation of China (Regional Project) (No. 32260162)
Project Title: The role and mechanism of a novel tumor suppressor ZBTB1 in metabolic reprogramming and chemotherapy resistance of triple-negative breast cancer
Duration: 2023.01-2026.12
Funding: 416,000 RMB, Principal Investigator
2. National Natural Science Foundation of China (Regional Project) (No. 31660325)
Project Title: The function and molecular mechanism of FBI-1 in regulating breast cancer stem cell properties and chemotherapy resistance
Duration: 2016.01-2020.12 (Completed)
Funding: 456,000 RMB, Principal Investigator
3. Jiangxi Provincial Natural Science Foundation (No. 20242BAB25499)
Project Title: Biological function and underlying mechanism of ZBTB4 in triple-negative breast cancer
Duration: 2024.06-2027.05
Funding: 100,000 RMB, Principal Investigator
Selected Publications (Corresponding Author & First Author)
1. Peng X, Guo G, Li S, Sun S, Ouyang C#, Cui J#. The regulatory mechanism of metabolic modification in breast cancer progression. Cells, 2026, 15(10): 929. (Corresponding Author)
2. Zhang P, Qian N, Lai H, Chen S, Wu K, Luo X, Lei B, Liu M, Cui J#. PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells. Genes, 2024, 15(10): 1316. (Corresponding Author)
3. Zhang P, Yang Y, Qian K, Li L, Zhang C, Fu X, Zhang X, Chen H, Liu Q, Cao S, Cui J#. A new tumor suppressor ZBTB1 modulates tamoxifen sensitivity and aerobic glycolysis by reducing HER2 levels in breast cancer.
J Biol Chem, 2020, 295(41): 14140-14152. (Corresponding Author)
4. Wang H, Li J, Xu W, Li C, Wu K, Chen G#, Cui J#. The mechanism underlying arsenic-induced PD-L1 upregulation in transformed BEAS-2B cells. Toxicol Appl Pharmacol, 2022, 435: 115845. (Corresponding Author)
5. Xu W, Ren M, Ghosh S, Qian K, Luo Z, Zhang A, Zhang C, Cui J#. Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy. Mediators Inflamm, 2020, 2020: 3645157. (Corresponding Author)
6. Cui J*, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, Wu R, Sun Y, Song H, Wei X, Jing P, Yang X, Zhang C. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells. Oncogene, 2015, 34(29): 3895-3907. (First Author, sole contribution: study design, experimental implementation and manuscript writing)
7. Cui J*, Germer K, Wu T, Wang J, Luo J, Wang SC, Wang Q, Zhang X. Crosstalk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res, 2012, 72(21): 5625-5634. (First Author)